Skip to main content
All lobbying filings

FEROX STRATEGIES

FEROX STRATEGIES filed a Q3 report for RARE DISEASE COMPANY COALITION on October 19, 2026, reporting $50,000 in lobbying income.

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

All filings by FEROX STRATEGIES · Everything RARE DISEASE COMPANY COALITION has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Health Issues

General issues related to rare disease treatment.

Trade (domestic/foreign)

General issues related to tariffs.

Taxation/Internal Revenue Code

General issues related to rare disease treatment development.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem